Compare Mesoblast Limited (MESO) vs VanEck Vietnam ETF (VNM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs VanEck Vietnam ETF — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while VanEck Vietnam ETF trades at $17.78. Which is the better fit depends on your goals.
| MESO | VNM | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | Sector/Thematic |
52-Week High | $20.96 | $19.80 |
52-Week Low | $12.88 | $16.34 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
VNM trades at $17.73, up 0.51% today, with a bullish technical signal driven by positive momentum indicators. The stock faces immediate resistance at $18, with support at $17. Recent news highlights Vietnam's economic challenges, including power grid strain and foreign capital outflows from Asian equities, potentially impacting the ETF's holdings.
Outlook remains cautious due to macroeconomic headwinds in Vietnam and underperformance relative to emerging markets. Investment opportunity hinges on FTSE Russell's EM reclassification attracting foreign inflows, but risks include heatwave-induced infrastructure stress and regional capital rotation away from AI-exposed markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About VanEck Vietnam ETF
VNM is the first and largest U.S.-listed ETF providing targeted exposure to the Vietnamese equity market. It tracks the MarketVector™ Vietnam Local Index, which includes publicly traded companies that are locally incorporated in Vietnam. It serves as a liquid, transparent vehicle for investors looking to participate in Vietnam's transition into a global manufacturing hub and its long-term potential for emerging market reclassification.
Read more on VNM →
